United Therapeutics Corporation (FRA:UTH)

Germany · Delayed Price · Currency is EUR

399.00

+3.50 (0.88%)

Last updated: Jan 27, 2026, 8:04 AM CET

Revenue

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015	Dec '14 Dec 31, 2014	Dec '13 Dec 31, 2013	Dec '12 Dec 31, 2012
Tyvaso Revenue	1.83B	1.62B
Remodulin Revenue	533.30M	538.10M
Orenitram Revenue	483.50M	434.30M
Unituxin Revenue	232.00M	238.70M
Adcirca Revenue	26.90M	23.80M
Total Product Sales Revenue	3.11B	2.86B
Revenue (Other)	22.90M	22.10M
Revenue (Total)	3.13B	2.88B

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015	Dec '14 Dec 31, 2014	Dec '13 Dec 31, 2013	Dec '12 Dec 31, 2012
United States Revenue	2.99B	2.74B
Rest-of-World Revenue	138.50M	137.70M
Revenue (Total)	3.13B	2.88B

Gross Profit

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015	Dec '14 Dec 31, 2014	Dec '13 Dec 31, 2013	Dec '12 Dec 31, 2012
Tyvaso Gross Profit	1.61B	1.44B
Remodulin Gross Profit	478.70M	490.70M
Orenitram Gross Profit	456.00M	405.90M
Unituxin Gross Profit	218.20M	224.30M
Adcirca Gross Profit	15.40M	13.70M
Total Product Sales Gross Profit	2.78B	2.57B
Gross Profit (Other)	-9.90M	-4.80M
Gross Profit (Total)	2.77B	2.57B

Updated Sep 30, 2025. Data Source: Fiscal.ai.